Page 1

November 15 , 2021 iBio ¡ Bio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update - Adds First New Anti - cancer Target for Development in Partnership with Rubryc Therapeutics - - Initiates Research Collaboration with UT Southwestern to Study Anti - fibrotics in Oncology - Establishes Partnership for Development of Painless Intradermal Vaccine Delivery - BRYAN , Texas , Nov. 15 , 2021 ( GLOBE NEWSWIRE ) -- iBio , Inc. ( NYSEA : IBIO ) ( " iBio " or the " Company " ) , a developer of next - generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System® , today announces its financial results for the fiscal quarter ended September 30 , 2021 and provides a corporate update . " We are continuing to accelerate the execution of our growth strategy as we start our fiscal year 2022 , " said Tom Isett , Chairman & CEO of iBio . " Having only just launched our oncology initiative six months ago , we have already created six active programs , including the two new ones announced today . In addition , we have advanced our novel COVID - 19 vaccine candidate to pre - IND , while concurrently building out our vaccine platform with new drug delivery technology partnerships . We have also acquired our cGMP manufacturing facility and taken sole ownership of our CDMO subsidiary , along with the attendant rights to manufacture biologics using our FastPharming System in the United States . We are confident that our investments over the past year in talent , technology , and infrastructure will return value to patients and shareholders as we go forward . " Fiscal First Quarter and Recent Business Developments : BIOPHARMACEUTICALS Therapeutics • In August 2021 , iBio added to its pipeline by in - licensing an IL - 2 sparing anti - CD25 antibody ( IBIO - 101 ) from RubrYc Therapeutics . Pre - clinical data shows that the molecule can deplete regulatory T cells from the tumor microenvironment and restore anti - tumor immunity , potentially representing an important new tool in the fight against cancer . • The Company continues to advance its endostatin E4 molecule for fibrotic diseases ( IBIO - 100 ) toward the clinic . Meanwhile , leveraging its investment in endostatin E4 ,